Audible Premium Plus. $0.99/mo for the first 3 months + $20 Audible credits. 12 days only. Get this deal. Cancel anytime.

S2 Ep8: The FDA Decision for Pompe Disease Therapy
Oct 28 2022
Length: 13 mins
Podcast

Failed to add items

Sorry, we are unable to add the item because your shopping cart is already at capacity.

Add to Cart failed.

Please try again later

Add to Wish List failed.

Please try again later

Remove from wishlist failed.

Please try again later

Adding to library failed

Please try again

Follow podcast failed

Please try again

Unfollow podcast failed

Please try again

S2 Ep8: The FDA Decision for Pompe Disease Therapy

Listen for free

View show details

Summary
The FDA is expected to announce the final decision for the dual therapy AT-GAA, which uses miglustat in combination with cipaglucosidase alfa for treating Pompe disease, an inherited and often times fatal disorder. Expert Barry Byrne discusses the characteristics of the condition and what this FDA decision will mean for treatment.

Show more Show less

Show more Show less

What listeners say about S2 Ep8: The FDA Decision for Pompe Disease Therapy

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews

No Reviews are Available

Report a review on Amazon